Novo Nordisk shares tank 20% after latest obesity drug disappoints
Danish diabetes and obesity drug specialist Novo Nordisk (NOVO-B:CPH) gave investors a nasty surprise on Friday (20 Dec) after revealing its next generation obesity treatment CagriSema fell short of inducing significantly more weight loss than rival Mounjaro made by Eli Lilly (LLY:NYSE), sending the shares spiraling down by more than 20%, wiping out more than £70 billion of market value.
The f...